- Home
- CTKB vs RCKT Comparison
CTKB vs RCKT Comparison
Compare CTKB & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTKB
- RCKT
- Stock Information
- Founded
- CTKB 1990
- RCKT 1999
- Country
- CTKB United States
- RCKT United States
- Employees
- CTKB N/A
- RCKT N/A
- Industry
- CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- CTKB Health Care
- RCKT Health Care
- Exchange
- CTKB Nasdaq
- RCKT Nasdaq
- Market Cap
- CTKB 718.8M
- RCKT 764.5M
- IPO Year
- CTKB 2021
- RCKT N/A
- Fundamental
- Price
- CTKB $2.83
- RCKT $2.77
- Analyst Decision
- CTKB Hold
- RCKT Buy
- Analyst Count
- CTKB 4
- RCKT 11
- Target Price
- CTKB $6.00
- RCKT $21.77
- AVG Volume (30 Days)
- CTKB 1.1M
- RCKT 7.4M
- Earning Date
- CTKB 05-08-2025
- RCKT 05-08-2025
- Dividend Yield
- CTKB N/A
- RCKT N/A
- EPS Growth
- CTKB N/A
- RCKT N/A
- EPS
- CTKB N/A
- RCKT N/A
- Revenue
- CTKB $197,050,000.00
- RCKT N/A
- Revenue This Year
- CTKB $3.25
- RCKT N/A
- Revenue Next Year
- CTKB $8.58
- RCKT N/A
- P/E Ratio
- CTKB N/A
- RCKT N/A
- Revenue Growth
- CTKB N/A
- RCKT N/A
- 52 Week Low
- CTKB $2.37
- RCKT $2.19
- 52 Week High
- CTKB $7.63
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- CTKB 43.14
- RCKT 27.94
- Support Level
- CTKB $2.37
- RCKT $2.19
- Resistance Level
- CTKB $2.61
- RCKT $2.67
- Average True Range (ATR)
- CTKB 0.18
- RCKT 0.54
- MACD
- CTKB 0.04
- RCKT -0.45
- Stochastic Oscillator
- CTKB 63.45
- RCKT 11.72
About CTKB Cytek Biosciences Inc.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.